Home
Search
Site map
Please choose
Austria
Belgium
Bulgaria
Canada
Denmark
Finland
France
Germany
Iceland
Israel
Italy
Lithuania
Luxembourg
Malta
Norway
Poland
Spain
Switzerland
United Kingdom
Corporate
Corporate information
Board of Directors
Dr. Martin Nicklasson
Mr. Domenico Scala
Mr. Hans-Beat Gürtler
Prof. Daniel Lew
Dr. Thomas M. Rinderknecht
Mr. Steven D. Skolsky
Dr. Thomas Werner
Management Committee
Mr. Ronald Scott
Dr. Ingrid Heinze-Krauss
Prof. Achim Kaufhold
Dr. Laurenz Kellenberger
Ms. Heidi McDaid
Company and subsidiaries
Patient Advocacy
Products
Toctino®
Development
Pipeline
Ceftobiprole
Alitretinoin
Isavuconazole
BAL30072
BAL101553
Research
Research strategy
Anti-infectives research
Oncology research
Research center China
Featured bugs
Pathogens
News and Media
News
Media contact
Scientific publications
Anti-infectives
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Archive
Oncology
2012
2011
2010
2009
Investor Relations
Corporate information
Corporate Governance
News and Media
Financial reports
Pipeline
Share information
Investors calendar
Investor Relations contact
News subscription
Careers
Contact us
Corporate
How to find us
Investor Relations / Media
Human Resources
Collaborations
Development
Pipeline
Ceftobiprole
Alitretinoin
Isavuconazole
BAL30072
BAL101553
Search
›› go!
Alitretinoin
Toctino® (alitretinoin) was developed and brought to market by Basilea. Basilea entered into a global agreement on Toctino® with Stiefel, a GSK company, in June 2012.
Info
Printable Version
IDSA Infectious Diseases Society of America
idsociety.org
National Eczema Association for Science and Education
nationaleczema.org
Doctorfungus
doctorfungus.org
